<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Immunovant Inc — News on 6ix</title>
<link>https://6ix.com/company/immunovant-inc</link>
<description>Latest news and press releases for Immunovant Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/immunovant-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583a778dffbe2df0fcc8c.webp</url>
<title>Immunovant Inc</title>
<link>https://6ix.com/company/immunovant-inc</link>
</image>
<item>
<title>Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-announces-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted-13</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-announces-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted-13</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous</description>
</item>
<item>
<title>Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-provides-corporate-updates-reports-120000558</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-provides-corporate-updates-reports-120000558</guid>
<pubDate>Fri, 06 Feb 2026 12:00:00 GMT</pubDate>
<description>IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and</description>
</item>
<item>
<title>Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-report-financial-results-third-222500688</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-report-financial-results-third-222500688</guid>
<pubDate>Fri, 23 Jan 2026 22:25:00 GMT</pubDate>
<description>DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Imm</description>
</item>
<item>
<title>Immunovant Announces Pricing of $550 Million Common Stock Financing</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-announces-pricing-550-million-common-stock-financing-2025-12-11</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-announces-pricing-550-million-common-stock-financing-2025-12-11</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a</description>
</item>
<item>
<title>Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-provides-corporate-updates-and-reports-financial-results-second-quarter</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-provides-corporate-updates-and-reports-financial-results-second-quarter</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment</description>
</item>
<item>
<title>Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-report-financial-results-second-quarter-ended-september-30-2025-and</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-report-financial-results-second-quarter-ended-september-30-2025-and</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended</description>
</item>
<item>
<title>Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-unveils-durability-and-treatment-free-six-month-remission-data-potential</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-unveils-durability-and-treatment-free-six-month-remission-data-potential</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up</description>
</item>
<item>
<title>Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-provides-corporate-updates-and-reports-financial-results-quarter-ended</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-provides-corporate-updates-and-reports-financial-results-quarter-ended</guid>
<pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
<description>Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s</description>
</item>
<item>
<title>Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-provides-corporate-updates-and-reports-financial-results-fourth-quarter-0</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-provides-corporate-updates-and-reports-financial-results-fourth-quarter-0</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>Immunovant’s new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially</description>
</item>
<item>
<title>Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-announces-next-phase-growth-roivant-including-changes-its-leadership-0</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-announces-next-phase-growth-roivant-including-changes-its-leadership-0</guid>
<pubDate>Mon, 21 Apr 2025 04:00:00 GMT</pubDate>
<description>Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D.</description>
</item>
<item>
<title>Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-announces-positive-results-batoclimab-myasthenia-gravis-mg-and-chronic</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-announces-positive-results-batoclimab-myasthenia-gravis-mg-and-chronic</guid>
<pubDate>Wed, 19 Mar 2025 04:00:00 GMT</pubDate>
<description>Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose</description>
</item>
<item>
<title>Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-host-investor-webcast-8-00-am-et-wednesday-march-19-review-results</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-host-investor-webcast-8-00-am-et-wednesday-march-19-review-results</guid>
<pubDate>Tue, 18 Mar 2025 04:00:00 GMT</pubDate>
<description>NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for</description>
</item>
<item>
<title>Immunovant Reports Financial Results for the Quarter Ended December 31, 2024</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-reports-financial-results-quarter-ended-december-31-2024-2025-02-06</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-reports-financial-results-quarter-ended-december-31-2024-2025-02-06</guid>
<pubDate>Thu, 06 Feb 2025 05:00:00 GMT</pubDate>
<description>Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves’ disease (GD) and</description>
</item>
<item>
<title>Immunovant Announces $450 Million Private Placement</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-announces-450-million-private-placement-2025-01-13</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-announces-450-million-private-placement-2025-01-13</guid>
<pubDate>Mon, 13 Jan 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people</description>
</item>
<item>
<title>Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-provides-development-updates-and-reports-financial-results-quarter-ended</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-provides-development-updates-and-reports-financial-results-quarter-ended</guid>
<pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
<description>Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data</description>
</item>
<item>
<title>Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-announces-oral-presentation-late-breaking-abstract-phase-2-graves-disease</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-announces-oral-presentation-late-breaking-abstract-phase-2-graves-disease</guid>
<pubDate>Tue, 29 Oct 2024 04:00:00 GMT</pubDate>
<description>NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people</description>
</item>
<item>
<title>Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors</title>
<link>https://6ix.com/company/immunovant-inc/news/ankyra-announces-appointment-of-dr-julia-butchko-and-ms-tara-withington-to-the-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/ankyra-announces-appointment-of-dr-julia-butchko-and-ms-tara-withington-to-the-board-of-directors</guid>
<pubDate>Mon, 23 Sep 2024 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors</description>
</item>
<item>
<title>Roivant Provides Update on Graves’ Disease Development Program</title>
<link>https://6ix.com/company/immunovant-inc/news/roivant-provides-update-graves-disease-development-program-2024-09-09-1</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/roivant-provides-update-graves-disease-development-program-2024-09-09-1</guid>
<pubDate>Mon, 09 Sep 2024 04:00:00 GMT</pubDate>
<description>High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-free</description>
</item>
<item>
<title>Immunovant Provides Update on Graves’ Disease Development Program</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-provides-update-graves-disease-development-program-2024-09-09</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-provides-update-graves-disease-development-program-2024-09-09</guid>
<pubDate>Mon, 09 Sep 2024 04:00:00 GMT</pubDate>
<description>High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-Free</description>
</item>
<item>
<title>Immunovant to Host Graves’ Disease Program Update on September 9, 2024</title>
<link>https://6ix.com/company/immunovant-inc/news/immunovant-host-graves-disease-program-update-september-9-2024-2024-09-05</link>
<guid isPermaLink="true">https://6ix.com/company/immunovant-inc/news/immunovant-host-graves-disease-program-update-september-9-2024-2024-09-05</guid>
<pubDate>Thu, 05 Sep 2024 04:00:00 GMT</pubDate>
<description>Investor webcast on Monday, September 9th at 8:00 a.m. ET NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage</description>
</item>
</channel>
</rss>